Evidence map›Paper›PMID 38274136›Full record

ArticleHealth science reports2024

Sequential therapy versus quadruple therapy for

Elham Tabesh, Farzad Yadmehr, Awat Feizi, Farzin Khorvash, Setayesh Sindarreh, Atousa Hakamifard

Open access · goldAbstract read
In one paragraph

Article in Health science reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Elham TabeshGastroenterology and Hepatology Research Center Isfahan University of Medical Sciences Isfahan Iran.
Farzad YadmehrDepartment of Infectious Diseases, School of Medicine Isfahan University of Medical Sciences Isfahan Iran.
Awat FeiziDepartment of Biostatistics and Epidemiology, School of Health Isfahan University of Medical Sciences Isfahan Iran.
Farzin KhorvashNosocomial Infection Research Center Isfahan University of Medical Sciences Isfahan Iran.
Setayesh SindarrehCancer Prevention Research Center Isfahan University of Medical Sciences Isfahan Iran.
Atousa HakamifardDepartment of Infectious Diseases, School of Medicine Isfahan University of Medical Sciences Isfahan Iran.ORCID 0000-0001-9456-2239
Isfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds and Aims: This controlled randomized clinical trial was designed to compare effectiveness, side effects, and severity of symptoms before and after therapy between quadruple (QT) and sequential regimens (SQ) for Methods: Patients were randomly allocated into two groups. Group A received a 14-day QT including pantoprazole 40 mg q12 h, bismuth subcitrate 240 mg q12 h, clarithromycin 500 mg q12 h, and amoxicillin 1000 mg q12 h and group B received ST including pantoprazole 40 mg q12 h and amoxicillin 1000 mg q12 h for the initial 5 days followed by pantoprazole 40 mg q12 h, clarithromycin 500 mg q12 h and tinidazole 500 mg q12 h for the next 5 days. Adverse drug reactions and patients' compliance were assessed after finishing the treatment course and also 4 weeks after. All patients were naive, therefore ST and QT were first-line therapies. To evaluate severity of symptoms we used Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) before taking the first dose of regimens, at the end of therapy, and also 4 weeks after (follow-up). Results: The mean age in Group A ( Conclusion: This study showed that ST can be used as an alternative first-line therapy to QT in patients with

Indexed as

eradicationHelicobacter pyloriquadruplesequential

Identifiers

PMID38274136
PMCPMC10808940
OpenAlexW4391223333

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.